Dong-A’s novel antibacterial agent receives positive results from Phase 3 clinical trial in severe s
Published: 2013-03-28 06:56:00
Updated: 2013-03-28 06:56:00
Trius Therapeutics, Inc. on March 25 announced top-line results from its ESTABLISH 2 Phase 3 clinical trial of tedizolid phosphate (DA-7218) for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including methicillin resistant Staphylococcus aureus (MRSA), Dong-A ST sa...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
